Kidney Cancer Scotland
Treatment decision making in localised kidney cancer
Kidney Cancer UK funded research on treatment decision making in localised kidney cancer. by; Katharina Beyer, PhD student at King’s College London There are many... Read More
Press Office
Welcome to Kidney Cancer UK & Kidney Cancer Scotland’s Press Office
For media enquiries about kidney cancer Kidney Cancer UK or Kidney Cancer Scotland, please contact us during office hours on 01223 870008 or you can email mp@kcuk.org.uk.
If you are a journalist with an urgent media inquiry outside of office hours, contact 07827-258756
Kidney Cancer UK Mission Statement:
Kidney Cancer UK is the UK’s leading kidney cancer charity. Our mission is to help reduce the harm caused by kidney cancer by increasing knowledge and awareness, providing patient information and by supporting research into the causes, prevention and treatment of the disease.
Latest press releases
Join our Rate My Plate Competition
COMPETITION TIME Inspired by National Curry Week, we invite you to join in our cooking competition. Why not have your own family curry party in... Read More
Kidney Cancer Patient Survey 2020
Click below to take our 7th annual patient survey today and make a difference
Cabo+Tecentriq combo shows promise in advanced ccRCC
Treatment with Cabometyx (cabozantinib) in combination with Tecentriq (atezolizumab) demonstrated promising clinical activity in patients with advanced clear cell renal cell carcinoma (ccRCC), according to... Read More
#LWKC Webinars 2020
Join us online
Every Penny Counts
Like everyone we have faced much adversity over the last 6 months. As a charity our team have shown incredible resilience to ensure longevity and... Read More
Kidney Cancer UK funded screening research update
Current evidence on screening for renal cancer Juliet Usher-Smith, Rebecca K. Simmons, Sabrina H. Rossi and Grant D. Stewart Renal cell carcinoma (RCC) rates are... Read More
SMC approves combination therapy for patients in Scotland
Kidney Cancer Scotland add their voice to those praising the Scottish Medicine Consortium’s (SMC) approval of the therapy Keytruda (pembrolizumab) in combination with Inlyta (axitinib)... Read More
Dive straight into the feedback!Login below and you can start commenting using your own user instantly